Akebia Europe

Company snapshot

Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease. Please review our social media guidelines at: https://akebia.com/social-media-guidelines/

• 3 approved product(s) across US/EU regulatory metadata.
• 25 active pipeline program(s) linked via ClinicalTrials.gov.
• 28 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Akebia Europe. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Akebia Europe.

1. Jun 8, 2026 Clinical update

   AKB-6548-CI-0013 — Phase 1

2. Jun 8, 2026 Clinical update

   vadadustat reference tablets — Phase 1

3. Jun 8, 2026 Clinical update

   Ferric Citrate 1 gram Oral Tablet — Approved

4. Jun 8, 2026 Clinical update

   Ferric Citrate 1 GM Oral Tablet [AURYXIA] — Phase 3

5. Jun 8, 2026 Clinical update

   Epoetin alga (Epogen)/vadadustat — Phase 3

View all clinical trial activity →

• What is Akebia Europe?

  Akebia Europe is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker AKBA. Primary therapeutic focus areas include Anemia, Anemia Associated With Chronic Kidney Disease, Anemia of Chronic Kidney Disease, Anemia, Iron Deficiency, Hyperphosphatemia

• Is Akebia Europe publicly traded?

  Yes. Akebia Europe is listed with ticker AKBA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Akebia Europe develop or market?

  We link 13 drug profile(s) where Akebia Europe is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/akebia-therapeutics#company-drugs.

• What are the latest developments for Akebia Europe?

  In the last 12 months our linked public records show 25 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Akebia Europe focus on?

  Akebia Europe focuses on Anemia, Anemia Associated With Chronic Kidney Disease, Anemia of Chronic Kidney Disease based on our analysis of their pipeline programs and drug development activities.